中文PortuguêsEspañolContact Us
Zhuhai Trinomab Biotech will install China's first native human mAb (monoclonal antibody) automated manufacturing platform at the International Health Port in Sanzao, Jinwan District, relying on GE Healthcare's FlexFactory design to expand biologics production.
A partnership agreement was signed between Trinomab, a high-tech company dedicated to R&D of immunotherapy and antibody compounds; and GE Heanlthcare, a world-leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, on Sept 5.
FlexFactory is a configurable single-use bio-manufacturing platform noted for faster deployment, multi-product processing, and accelerated production with flexible, scalable processes.
Signing ceremony
Not only can it make Trinomab Biotech's biopharmaceutical manufacturing more centrally automated and integrated, it reportedly can also help other pharmaceutical enterprises in the district with its modularized production line.
Costing 1 billion yuan ($146.3 million), construction of the first phase will soon commence. Once operational in 2020, the project will encompass 200-litre and 1,000-litre production lines capable of achieving an output value of $4 billion.
Meanwhile, the project will signal the Jinwan pharmaceutical industry to shift its industrial structure from chemical medicine to biomedicine, which is of higher quality and added value.
Trinomab Biotech is committed to the discovery and industrialization of native human mAb with its self-owned HitmAb® technology. Since beginning in 2015, it has discovered antibodies for nearly 10 infectious diseases, tumors, and autoimmune illnesses.
Ground breaking [Photos by Zhang Zhou / Zhuhai Daily]
